Regimen for the Treatment of Cachexia in Subjects With NSCLC

Completed · Phase 2

Conditions studied: Cachexia

In brief

Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not utilized. To switch the nutritional system from a hypercatabolic to a normal nutritional state, therapy must block multi-factorial stress signaling a threshold of activation. Consistent with the synergistic hypothesis, propranolol and etodolac have been evaluated in subjects with advanced cancer demonstrating cachexia. This trial will evaluate the safety and efficacy of VT-122 in subjects with NSCLC who have hypercatabolic cachexia.

Key facts

Study ID

NCT00527319

Run by

Vicus Therapeutics

People needed

37

Starts

2007-01-01

Expected to finish

2008-09-01

Last updated by the study team

2013-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with NSCLC
• Demonstrating average weight loss of 5% within 2 months prior to enrollment
• Heart rate of 72 bpm or greater
• Negative pregnancy test (female patients of child bearing age)
• Able to give informed consent
• Able to be administered medication
• Able to take food and defined nutritional support
• Have not been on beta-blockers for a minimum of 1 week prior to administration of the medication screening dose
• Have not undergone surgery for at least 2 weeks prior to entry into trial
• Have not been on chemotherapy, immunotherapy, biologic therapy, radio therapy, and experimental therapy for a minimum of two weeks prior to medication screening dose and during their participation in this trial
• An expected survival for a minimum of 12 weeks

You may not qualify if…

• Contraindication to nonsteroidal antiinflammatory drugs (NSAIDs) and beta blockers
• Blood pressure less than 100/65
• Weight loss of 15% within 2 months prior to recruitment
• Hypersensitivity reaction to the active components in VT-122
• History of myocardial infraction within the past 3 months
• Congestive heart failure (as determined by symptoms and ECG)
• A-V block of second or third degree
• Unstable angina
• Uncontrolled diabetes
• Unable to be assessed for grip strength
• A positive pregnancy test
• Chronic infection or sepsis
• History of bleeding disorders
• Patients with peripheral edema
• Patients on digoxin or other chronotropic drugs
• Patients with evidence of severe dehydration
• Patients with evidence of ascites

Where it is running

• First Dynamic Health Care Services, Inc. — Waco, Texas, United States
• Rajalakshmi Nursing Home — Bangalore, India
• Nizam Institute of Medical Sciences — Hyderabaad, India
• Orchid Nursing Home — Kolkata, India
• Shatabdi Super Specialty Hospital — Nashik, India
• All India Institute of Medical Sciences — New Delhi, India
• Indraprastha Apollo Hospital — New Delhi, India
• Deenanath Mangeshkar Hospital — Pune, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.